What HB 7125 (and Parity Legislation Being Introduced Across the U.S.) Does and Does Not Do:
This legislation DOES require insurers to submit analyses demonstrating how they are in compliance with the Federal Parity Law, which has existed for over a decade, in a format that is in accordance with federal guidance issued on April 23, 2018 (see pages 13-17).
This legislation DOES NOT require insurers to report anything related to parity that is beyond what is required by the Federal Parity Law. The key terms used in this legislation are the same terms in the regulations for the Federal Parity Law.
This legislation DOES require insurers to prove to the state that they have done their due diligence to determine that they comply with the Federal law, a landmark antidiscrimination law. There is no possible way an insurer can assert that it complies with this law if it has not performed internal comparative analyses.
This legislation DOES NOT require extra administrative burden on the part of insurers, unless they are not complying with the law. If they are in fact in compliance with the law, this should be simple information to produce.
This legislation DOES eliminate barriers to lifesaving treatments for opioid use disorder. When people affected by addiction are ready to seek treatment, any administrative hurdles could directly lead to death.
This legislation DOES NOT eliminate an insurer’s ability to perform utilization management for medication-assisted treatment. It just prohibits the types of utilization review that inhibit initial uptake of medication-assisted treatment, which can be quite deadly.